Sai Life Sciences IPO subscribed overall 10.27 times on the last day, while A retail quota was subscribed 1.39 times, QIB was subscribed 29.78 times, and NII quota subscribed by 4.99 times respectively.
Details About Sai Life Sciences IPO
Sai Life Sciences got approval from SEBI for an IPO of ₹3,042.62 crores to raise funds and maintain financial stability. The face value of each share was Rs 1. Moreover, the company has set up a price band between ₹522 to ₹549 per share. In this IPO total of 27 shares were available in 1 lot size for the minimum Retail category and for the maximum retail category, 351 shares were available in 13 lot sizes, For S-HNI (Min) total of 378 shares were available in 14 lot sizes. While, as for B-HNI Minimum total of 1,836 shares was available in 68 lot sizes.
To invest in this IPO, each investor category has specific investment amounts:
- Retail Investors: Minimum investment of ₹14,823 and maximum investment of ₹192,699.
- Small HNI (S-HNI): Minimum investment of ₹207,522.
- Big HNI (B-HNI): Minimum investment of ₹1,007,964.
Subscription duration of Sai Life Sciences IPO
The Sai Life Sciences IPO subscription opening date was 11 December and the close date was 13 December. The Sai Life Sciences IPO allotment was finalized on December 16 and the IPO listing is on December 18.
Funds Deployment of This Company
The company plans to use the money raised from the new shares for the following purposes:
- Repayment/prepayment in full or part, of all or certain outstanding borrowings availed by the Company and
- General corporate purposes
About Sai Life Sciences IPO
Established in January 1999, Sai Life Science Limited works with innovative pharma and biotech companies by providing services across drug discovery, development, and manufacturing of small-molecule new chemical entities (NCE). Sai Life Sciences Limited is a contract research, development, and manufacturing organization (CRDMO). The company uses its scientific knowledge and skills to deal with critical healthcare challenges. In the future, they aim to develop medicines to treat conditions that are not curable right now and make a huge difference in the future of healthcare. Their services can be customized according to the customer’s needs, whether it’s a small client, a large biotech company, or a global pharmaceutical company making them adaptable and unstoppable. They are growing more in CRDMO than their competitors by earning revenue CAGR (Compound Annual Growth Rate) and EBITDA CAGR from fiscal year 2022 to 2024. They have always delivered a wide set of NCE development programs for their customers over the past 24 years. Quality, price, and responsiveness are the main 3 key areas where they have shown incredible value to its clients.
Sai Life Sciences IPO Financial Background
The company reported revenue of ₹1,494.27 crores in 2024 against ₹1,245.11 crores in 2023. The company reported a Profit of ₹82.81 crores in 2024 against a Profit of ₹9.99 crores in 2023.
